Clinical Trial

Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 17, 2025 (before its estimated May 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is an open-label, multicenter Phase 1b clinical study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of HC006 in combination with a PD-1 inhibitor in patients with advanced solid tumors. The trial is divided into two stages: dose-escalation and dose expansion. First, the dose-escalation study is completed to determine the recommended dose for subsequent extension studies, and then the dose expansion study is conducted in the proposed tumors with potential treatment benefits.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-30.
Status change: Not Yet Recruiting → Recruiting 2025-07-14
Trial Details
NCT Number NCT06963814
Lead Sponsor HC Biopharma Inc.
Conditions Advanced Cancer
Enrollment 252 participants
Start Date 2025-07-04
Primary Completion 2026-05-30 (estimated)
Study Completion 2027-05-30 (estimated)
Updated on ClinicalTrials.gov 2025-07-17